| Date | Time | Source | Headline | Symbol | Company |
| 08/07/2009 | 6:01PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 08/05/2009 | 6:03PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 08/05/2009 | 6:01PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 08/04/2009 | 5:16PM | Edgar (US Regulatory) | Quarterly Report (10-Q) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 08/04/2009 | 4:06PM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 08/04/2009 | 4:00PM | Business Wire | Allos Therapeutics Reports Second Quarter 2009 Financial Results | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 07/23/2009 | 10:06AM | Business Wire | Allos Therapeutics Launches Peripheral T-Cell Lymphoma Website | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 07/22/2009 | 8:00AM | Business Wire | Allos Therapeutics to Report Second Quarter 2009 Results on August 4, 2009 | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 07/20/2009 | 8:04AM | Edgar (US Regulatory) | Securities Registration: Employee Benefit Plan (S-8) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 07/20/2009 | 8:00AM | Edgar (US Regulatory) | Securities Registration Statement (simplified form) (S-3) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 07/20/2009 | 7:55AM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 07/07/2009 | 9:03AM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 07/07/2009 | 8:07AM | Marketwired | BridgewaterEquity.com Free Fundamental Sector & Market Research on OCR, GGC, NWD, MPW, ALTH and NEXM | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 07/07/2009 | 8:00AM | Business Wire | Allos Therapeutics Completes Enrollment in Randomized Phase 2b Trial of Pralatrexate in Patients with Advanced Non-Small Cell... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 06/29/2009 | 8:40AM | PR Newswire (US) | InvestorSoup.com Researches Market Movers: Applied Materials, Allscripts-Misys, Allos, ValueVision, BGC Partners and Warren Reso | NASDAQ:ALTH | |
| 06/23/2009 | 6:46PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 06/23/2009 | 6:45PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 06/23/2009 | 6:44PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 06/23/2009 | 6:43PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 06/23/2009 | 6:41PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 06/23/2009 | 6:41PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 06/23/2009 | 6:40PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 06/17/2009 | 5:09PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 06/12/2009 | 12:53PM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 06/02/2009 | 6:05AM | Edgar (US Regulatory) | Proxy Statement (definitive) (DEF 14A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 06/01/2009 | 9:00AM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 05/30/2009 | 8:00AM | Business Wire | Allos Therapeutics Reports Updated Data from Pivotol Phase 2 PROPEL Study of Pralatrexate at 45th ASCO Annual Meeting | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 05/26/2009 | 8:05AM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 05/26/2009 | 8:00AM | Business Wire | Allos Therapeutics Announces FDA Accepts Pralatrexate NDA for Filing and Grants the Application Priority Review Status | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 05/14/2009 | 6:15PM | Business Wire | Allos Therapeutics Announces Updated Data from Pivotol Phase 2 PROPEL Study of Pralatrexate to be Presented at ASCO 2009 | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |